For The Biome Delivers Highly Anticipated Formulation of Cistus Incanus to North American Market, Mediterranean Herb Clinically Proven to Strengthen Immune Response in 2 Hours
March 30, 2021 08:50 ET | For The Biome
DUMMERSTON, VT, March 30, 2021 (GLOBE NEWSWIRE) -- For The Biome, founded by industry innovator and master herbalist Paul Schulick, has launched Immune Therapy Cistus+ Infusion, a groundbreaking...
ritter.jpg
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.
May 22, 2020 12:35 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction...
ritter.jpg
Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC
April 16, 2020 14:07 ET | Ritter Pharmaceuticals, Inc.
Special Meeting of Ritter Pharmaceuticals, Inc. Stockholders to Vote on Proposed Merger Scheduled for May 14, 2020 LOS ANGELES , April 16, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc....
ritter.jpg
Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019
March 31, 2020 17:27 ET | Ritter Pharmaceuticals, Inc.
Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES, March 31, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”,...
ritter.jpg
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
January 21, 2020 09:15 ET | Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
ritter.jpg
Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update
November 13, 2019 19:35 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
ritter.jpg
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
June 27, 2018 07:05 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split
March 01, 2018 16:20 ET | Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 01, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
October 31, 2017 06:45 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
October 03, 2017 12:00 ET | Ritter Pharmaceuticals
Los Angeles, California,, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...